1992
DOI: 10.1038/bjc.1992.188
|View full text |Cite
|
Sign up to set email alerts
|

Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
5
0

Year Published

1993
1993
2000
2000

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 30 publications
(5 citation statements)
references
References 23 publications
0
5
0
Order By: Relevance
“…HILP for softtissue sarcomas is an attractive mode of therapy considering that 15-20 times higher regional cytostatic concentrations can be reached compared with systemic administration with minimal systemic toxicity (12). However, the results of HILP for extremity soft-tissue sarcomas with various cytostatic agents are not impressive (13)(14)(15).…”
mentioning
confidence: 99%
“…HILP for softtissue sarcomas is an attractive mode of therapy considering that 15-20 times higher regional cytostatic concentrations can be reached compared with systemic administration with minimal systemic toxicity (12). However, the results of HILP for extremity soft-tissue sarcomas with various cytostatic agents are not impressive (13)(14)(15).…”
mentioning
confidence: 99%
“…Before and during the perfusion, 10 ml perfusate samples were collected at 10 min intervals to determine the ultrafiltrated platinum (fPt) levels as previously extensively published. 19 The leakage into the systemic circulation was also determined by measuring the patients fPt plasma concentrations at the end of each perfusion procedure both before and after restoration of the circulation to the perfused limb and during the 7 days following 55 the perfusion. For fPt perfusate elimination kinetics, data were subjected to logarithmic regression analysis (concentration = A.e -k.t ).…”
Section: Methodsmentioning
confidence: 99%
“…A number of agents have been administered via ILP including cisplatin [39,[56][57][58][59][60], cisplatin and etoposide [61], melphalan and actinomycin D [62], DTIC [63,64], or IL-2 and LAK cells [64,65]. Despite the substantial clinical experience with other agents it does not appear that any have superior efficacy or less toxicity than melphalan alone [66].…”
Section: Isolated Limb Perfusion With Other Agentsmentioning
confidence: 99%
“…Cisplatin administered via ILP has been evaluated by a number of centers [39,[56][57][58][59][60][61]661. Cisplatin appears to be a suitable agent for administration in the isolated perfusion setting, in that its concentration in tumor tissue appears to be selectively increased in the presence of mild hyperthermia, and significant tumor levels can be achieved with relatively short exposure [56-581.…”
Section: Isolated Limb Perfusion With Other Agentsmentioning
confidence: 99%